Predict your next investment

Corporation
HEALTHCARE | Biotechnology
curevac.com

See what CB Insights has to offer

Founded Year

2000

Stage

IPO | IPO

Total Raised

$1.281B

Date of IPO

8/14/2020

Market Cap

20.76B

Stock Price

60.75

About CureVac

CureVac, a German clinical stage biopharmaceutical company, serves the field of mRNA-based technology platforms for medical purposes, in which unmodified mRNA is specifically optimized and formulated. CureVac has been developing mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive. Moreover, CureVac's technology RNArt is designed as a molecular therapy to trigger the body's own production of therapeutic proteins without stimulating the immune system.

CureVac Headquarter Location

Friedrich-Miescher-Str. 15

Tubingen, 72076,

Germany

+49 7071 9883 - 0

Latest CureVac News

After late-stage trial setback, CureVac terminates COVID-19 vaccine contracts with WACKER, Celonic

Sep 14, 2021

by Joseph Keenan Sep 14, 2021 9:55am CureVac has terminated manufacturing contracts with WACKER and Celonic as part of a strategic decision to adjust the company’s long-term presence in the external European mRNA manufacturing network. (CureVac) After its first-generation COVID-19 vaccine posted efficacy of just 47% in a late-stage trial, CureVac is scaling back its manufacturing ambitions in Europe. Tuesday, the German biotech said it has terminated manufacturing contracts with WACKER and Celonic as part of a strategic decision to reduce its European manufacturing footprint. The cancellations won’t affect CurVac’s agreements with Rentschler Biopharma or Novartis for the production and formulation of mRNA. The company also plans to have enough clinical trial material for CV2CoV, a second-gen COVID-19 vaccine candidate under joint development with GlaxoSmithKline. The decision comes amid the biopharma industry's "continuous increase," in mRNA capacity, CureVac Chief Operating Officer Malte Greune, Ph.D., said in a statement. That capacity increase, combined with the "large-scale vaccination efforts" already underway, have "strongly changed the demand for our first-generation COVID-19 vaccine,” Greune added.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing CureVac

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned CureVac in 3 CB Insights research briefs, most recently on Jun 24, 2021.

Expert Collections containing CureVac

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CureVac is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

I

Infectious Disease

2,263 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

CureVac Patents

CureVac has filed 232 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • Vaccines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/18/2019

9/7/2021

Immunology, Immune system, Clusters of differentiation, Molecular biology, Vaccines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/18/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/7/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Immunology, Immune system, Clusters of differentiation, Molecular biology, Vaccines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CureVac Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CureVac Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.